EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Response to subthreshold micropulse laser treatment in the prophylaxis of diabetic macular oedema: A preliminary study

Barbara Sabal iD, Edward Wylęgała, Sławomir Teper

Acta Ophthalmologica · 2026

DOI: 10.1111/aos.17548 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2026. Verfasst von Barbara Sabal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Visual Acuity, Laser Coagulation. Die Arbeit nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the use of subthreshold micropulse laser (SMPL) in the prevention and management of mild diabetic macular oedema (DME).

Methods

This prospective, randomised and sham‐controlled study included 159 eyes (123 patients) with diabetic retinopathy, central retinal thickness (CRT) ≤ 325 μm, and best‐corrected visual acuity (BCVA) ≥ 80 ETDRS letters. The participants were assigned to either SMPL treatment ( n = 103) or sham therapy ( n = 56). Ophthalmic evaluations were performed at baseline (T1), 3 months (T2) and 12 months (T3) to assess BCVA and optical coherent tomography (OCT) parameters, including CRT, macular thickness (MT), macular volume (MV), and hyperreflective spots (HRS).

Results

In the SMPL group, BCVA improved after 3 months (T2 > T1; p = 0.002); MT decreased after 12 months (T2, T1 > T3; p < 0.001); MV decreased after 12 months (T2, T1 > T3; p < 0.001); HRS count decreased after 3 and 12 months (T1 > T2, T3, p < 0.001). The decrease in CRT after 3 months was greater in the SMPL group ( p = 0.003). The need for rescue therapy was lower in the SMPL group (9.7% vs. 19.6%, p = 0.007). BCVA, CRT, MV, MT and HRS remained stable in the sham group, while microaneurysms count was stable in both groups.

Conclusion

SMPL is safe and effective for the prophylaxis of mild DME, as it reduces MT and MV while keeping BCVA stable. The decreased need for rescue anti‐vascular endothelial growth factor therapy suggests that it may delay or reduce intravitreal injections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyVisual AcuityLaser CoagulationMacula LuteaHumansFemaleMaleProspective StudiesTomography, Optical CoherenceMiddle AgedFollow-Up StudiesTreatment OutcomeAgedFluorescein Angiography

Stichwörter der Autor:innen

diabetic macular oedemadiabetic retinopathyprophylaxissubthreshold micropulse laser

Autor:innen und Institutionen

  • Chair and Clinical Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
  • Department of Ophthalmology, John Paul II Municipal Hospital, Rzeszow, Poland.
  • Scientific Research Facility, Branch in Bielsko-Biala, Medical University of Silesia, Katowice, Poland.

ORCID-Profile: Barbara Sabal

Zitieren

APA

Sabal, B., Wylęgała, E., & Teper, S. (2026). Response to subthreshold micropulse laser treatment in the prophylaxis of diabetic macular oedema: A preliminary study. Acta Ophthalmologica. https://doi.org/10.1111/aos.17548

Vancouver

Sabal B, Wylęgała E, Teper S. Response to subthreshold micropulse laser treatment in the prophylaxis of diabetic macular oedema: A preliminary study. Acta Ophthalmologica. 2026. doi:10.1111/aos.17548

BibTeX
@article{Sabal2026,
  author = {Sabal, Barbara and Wylęgała, Edward and Teper, Sławomir},
  title = {Response to subthreshold micropulse laser treatment in the prophylaxis of diabetic macular oedema: A preliminary study},
  journal = {Acta Ophthalmologica},
  year = {2026},
  doi = {10.1111/aos.17548}
}
Kostenlos starten →